DealHorizon - the faster, easier way to create and share business plans

Companies > Targovax

Please log in to edit this profile

Elevator Pitch	OSLO, Norway--(BUSINESS WIRE)--Targovax, an oncology biopharma company, today announced that it has secured NOK 13 million (USD 2.2 million) from a consortium to develop a pancreatic cancer vaccine.
Industry Focus
Category	Companies - Early Stage

Contact Information

	Norway

Email	Please log in
Web	http://www.targovax.com

Compete.com

Investment Rounds

Series A

Amount: $13,000,000

Closed: February 1, 2012

Click here for press release

Investors

Reputation

Be the first to recommend Targovax! Log in

Data Sources

Public information, member edits, and the DealHorizon.com team.

Office Location

Statistics

Founded: Unknown [Edit]

Ownership: Private [Edit]

Revenue: Unknown [Edit]

Employees: Unknown [Edit]

Search Site

Edit/Update

Flag Abuse

Followers

Please log in
Note: Once associated with a listing, Executives are automatically included as followers of that listing. Listing creators are also automatically added as followers.